Better tests for fatty liver disease in people with metabolic issues
Part of Digestive system clinical trials.
This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need to have type 2 diabetes or at least one sign of metabolic syndrome, like a large waistline, high blood pressure, or abnormal cholesterol.
- You must be willing to have a liver biopsy.
- You cannot have other liver diseases, such as hepatitis B or C.
- You must not drink heavily (more than 1 drink per day for women or 2 per day for men).
- You need to be willing to follow study rules, which may include fasting before tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a way to find liver scarring (fibrosis) early in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. Early detection may help prevent serious liver damage.
This study tests a better way to check for advanced liver scarring (cirrhosis) in people with fatty liver disease. It might help you avoid unnecessary procedures if you have metabolic liver disease and are at risk of serious liver problems.
This trial studies people with liver disease linked to alcohol use or metabolic syndrome (a cluster of conditions like weight gain and insulin resistance). It uses recent standard-of-care liver biopsy results to better understand these chronic liver problems and how they relate to cancer risk.
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
This study looks at blood cells and factors in people with metabolic diseases like fatty liver, prediabetes, or type 2 diabetes. It aims to better understand these conditions by comparing them with healthy volunteers.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
Hear when a new Metabolic Associated Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.